Production and clinical development of a Hansenula polymorpha-derived PEGylated hirudin

Seminars in Thrombosis and Hemostasis

Volumn 27, Issue 4, 2001, Pages 357-371

  Avgerinos, G C ^a   Turner, B G ^a   Gorelick, K J ^a   Papendieck, A ^a   Weydemann, U ^a   Gellissen, G ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Clinical development; Hansenula polymorpha; Hirudin; Manufacturing; PEG hirudin

Indexed keywords

HEPARIN; HIRUDIN; MACROGOL;

AGED; BYPASS SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG STRUCTURE; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HANSENULA POLYMORPHA; HEART MUSCLE ISCHEMIA; HEMODIALYSIS; HUMAN; IMMUNOGENICITY; MOLECULAR WEIGHT; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOCYTOPENIA;

ANIMALS; ANTITHROMBINS; CLINICAL TRIALS; HIRUDIN THERAPY; HIRUDINS; HUMANS; INDUSTRIAL MICROBIOLOGY; PHARMACOKINETICS; PICHIA; TRANSFORMATION, GENETIC;

EID: 0034877519     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-16889     Document Type: Review

References (44)

1. Über die einwirkung eines sekretes des blutegels auf die gerinnbarkeit des blutes
2. Proteinase inhibitors of the leech Hirudo medicinalis (hirudins, bdellins, eglins)
3. Transformation of the methylotrophic yeast Hansenula polymorpha by autonomous replication and integration vectors
4. Heterologous protein production in methylotrophic yeasts
5. Recombinant hepatitis B vaccines - Characterization of the viral disease and vaccine production in the methylotrophic yeast, Hansenula polymorpha
6. An expression system matures: A highly efficient and cost-effective process for phytase production by recombinant strains of Hansenula polymorpha
7. Hansenula
8. Gene expression in methylotrophic yeasts
9. Molecular cloning and characterization of a gene coding for methanol oxidase in Hansenula polymorpha
10. The methylotrophic yeast Hansenula polymorpha: A versatile cell factory
11. α-Factor-directed synthesis and secretion of mature foreign proteins in Saccharomyces cerevisiae
12. Prepro a-factor has a cleavable signal sequence
13. Cloning of the Schwanniomyces occidentalis glucoamylase gene (GAM1) and its expression in Saccharomyces cerevisiae
14. Cloning and sequence analysis of cDNA for precursor of a crustacean hyperglycemic hormone
15. High-level secretion of hirudin by Hansenula polymorpha - Authentic processing of three different preprohirudins
16. An efficient transformation procedure enabling long-term storage of competent cells of various yeast genera
17. Assay of hirudin in plasma using a chromogenic thrombin substrate
18. Transformation of the methylotrophic yeast Hansenula polymorpha by autonomous replication and integration vectors
19. General tolerability and effects on clotting parameters after single i.v. and s.c. bolus administration of recombinant hirudin (LU 52369) in man
20. Pharmacokinetics and anticoagulant effect of hirudin in man
21. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein
22. Clinical pharmacology of polyethylene glycol-L-asparaginase
23. Molecular design of hybrid tumor necrosis factor-alpha III: Polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation
24. PEGylation of interleukin-6 effectively increases its thrombopoietic potency
25. Pharmacodynamic and safety results of PEG-hirudin in healthy volunteers
26. Safety and anticoagulant effects of intravenous PEG-hirudin in elderly and healthy young subjects
27. Pharmacology of r-hirudin in renal impairment
28. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients
29. Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure
30. Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development
31. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: Comparison of PEG-hirudin and unfractionated heparin
32. Thrombin inhibition and intracoronary thrombus formation: Effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery
33. Inhibition of neointimal proliferation after coronary angioplasty by low-molecular-weight heparin (Clivarine) and polyethyleneglycol-hirudin
34. Adventitial proliferation after coronary stent angioplasty: Temporal pattern and response to antithrombotic intervention
35. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis
36. Comparative efficacy of recombinant hirudin and PEG-hirudin in a dog model of hemodialysis
37. PEG-hirudin compared with unfractionated heparin reduces the burden of silent ischemia in patients with acute coronary syndromes
38. A randomized trial of safety and efficacy of long-acting PEG-hirudin in patients with unstable angina and non-Q-wave myocardial infarction
39. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina
40. A comparison between the use of recombinant hirudin and heparin during hemodialysis
41. Pharmokinetics of PEG-hirudin in subjects with various degrees of renal function